

NOTE: This updated guidance from Home State Health regarding Synagis (palivizumab) eligibility replaces the previous letter dated September 2019. Due to recent changes in MoHealth Net approval criteria for Synagis (palivizumab), we have updated our guidance on this important preventative health service for our most vulnerable members.

An Important Note from Home State Health's Medical Director Synagis Injections

Home State Health is actively encouraging appropriate use of Synagis® injections for prophylaxis against RSV, and would like to assist in ensuring that your patients receive this treatment if it is indicated. We have included the current guidance from Missouri Health Net regarding inclusion criteria for this treatment as well as other resources to help patients receive this treatment when appropriate.

Please use the below listed MO Health Net Synagis® guidelines to assist in determining if Synagis® is appropriate for your patient:

- Claim is during RSV Season (November through April) **AND**
- For prematurity:
 - Participant aged ≤ 12 months and born ≤ 28 weeks gestation **OR**
 - Participant aged ≤ 6 months and born between 29 and 32 weeks gestation **OR**
 - Participant aged ≤ 3 months and born between 32 and 35 weeks gestation **AND**
 - Enrolled in child care **OR**
 - Has siblings that are < 5 years of age **OR**
- For Chronic Lung Disease:
 - Participant aged < 12 months and born < 32 weeks gestation with Chronic Lung Disease **AND**
 - Required more than 21 % oxygen for 28 days following birth **AND**
 - Currently requiring medical therapy (oxygen on a continuous basis, bronchodilator, diuretic, corticosteroid or ventilator dependent) **OR**
 - Participant aged < 24 months and born < 32 weeks gestation with Chronic Lung Disease **AND**
 - Required more than 21 % oxygen for 28 days following birth **AND**
 - Currently requiring medical therapy (oxygen on a continuous basis, bronchodilator, diuretic, corticosteroid or ventilator dependent) **OR**
- For Congenital Heart Disease:
 - Participant aged ≤ 24 months with hemodynamically significant cyanotic and acyanotic congenital heart disease **AND**

Contact Provider Partnership:

HomeStateHealth.com

Allwell.HomeStateHealth.com

Ambetter.HomeStateHealth.com

Home State: 1-855-694-4663

MAPD: 1-855-766-1452 / D-SNP: 1-833-298-3361 / TTY:711

Ambetter: 1-855-650-3789 TTY/TDD: 1-877-250-6113

- Receiving medication to control CHF (Digoxin, Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitroglycerin, Anti-Coagulants, Diuretics, or Supplemental Oxygen) **OR**
- Moderate to severe Pulmonary Hypertension **OR**
- Cyanotic Heart Disease **OR**
- For congenital abnormality of the airway or neuromuscular disease that impairs ability to clear secretions: Participant aged < 12 months **OR**
- For severe immunodeficiencies that may benefit from prophylaxis as determined by clinical consultant review: Participant aged ≤ 24 months

Synagis® is usually given as five monthly intramuscular injections during the RSV season, which generally lasts from November through April. The exceptions to this include the following:

1. Infants born before 29 weeks, but during the RSV season, may require fewer than five doses.
2. Monthly prophylaxis should be discontinued in any child who experiences a breakthrough RSV hospitalization.

Information about RSV census regional trends can be found on the CDC website:

<http://www.cdc.gov/surveillance/nrevss/rsv/region.html#midwest>.

Missouri Health Department Synagis Clinical Edit Revised on October 10, 2019 link:

<https://dss.mo.gov/mhd/cs/pharmacy/pdf/synagis.pdf>

If your patients do indeed meet the above guidelines for Synagis®, it can be administered either in the office, or if necessary, at home. If administered in the office, charges for the injection administration should be billed directly to Home State Health Plan on a (HCFA) CMS 1500 claim form using CPT code 96372. You can also bill for an appropriate office visit on the same day as the administration of the drug. As with other injectables, the Synagis® itself is billed to MO HealthNet fee for service.

If necessary, Synagis® can also be administered by home health care nurses; nursing visits must be prior authorized by Home State Health Plan through our Prior Authorization Department at fax number 855-286-1811.

Denial Criteria:

- Therapy will be denied if no approval criteria are met
- Therapy exceeds 5 doses per RSV season.

Contact Provider Partnership:

HomeStateHealth.com

Allwell.HomeStateHealth.com

Ambetter.HomeStateHealth.com

Home State: 1-855-694-4663

MAPD: 1-855-766-1452 / D-SNP: 1-833-298-3361 / TTY:711

Ambetter: 1-855-650-3789 TTY/TDD: 1-877-250-6113

An important
message from
Provider Relations



Home State Health will assist, if necessary, in coordinating care with your office, to ensure medication compliance.

During flu season, please encouraged all infants, children, and their contacts to be immunized against influenza beginning at 6 months of age. Synagis and the influenza vaccine may be administered in the same visit to qualifying infants.

Sincerely,

A handwritten signature in black ink, appearing to read "Nadim Kanafani".

Nadim Kanafani, MD
Medical Director
Home State Health
11720 Borman Drive
St. Louis, MO 63146

Contact Provider Partnership:

HomeStateHealth.com

Allwell.HomeStateHealth.com

Ambetter.HomeStateHealth.com

Home State: 1-855-694-4663

MAPD: 1-855-766-1452 / D-SNP: 1-833-298-3361 / TTY:711

Ambetter: 1-855-650-3789 TTY/TDD: 1-877-250-6113